Latest Breaking News On - Petros grivas - Page 1 : comparemela.com

Advances With Erdafitinib Exemplify the Push For Precision Medicine in Urothelial Cancer

Petros Grivas, MD, PhD, expands on key updates in the second-line management of urothelial cancer.

United statesUniversity of washingtonPetros grivasMiami cancer instituteGenitourinary cancers programUniversity of washington school medicineSeattle cancer care alllianceWashington schoolClinical research divisionFred hutchinson cancer center

Grivas Spotlights Advances With Immunotherapy-Based Approaches in Urothelial Cancer

Grivas Spotlights Advances With Immunotherapy-Based Approaches in Urothelial Cancer
onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.

United statesUniversity of washingtonPetros grivasGenitourinary cancers programUniversity of washington school medicineDivision of oncologyClinical research divisionFred hutchinson cancer centerDepartment of medicineSeattle cancer care alllianceWashington schoolNew england journal

How to Self-Advocate During Bladder Cancer Awareness Month

Getting second opinions is highly encouraged for patients recently diagnosed with bladder cancer because “it’s not one size fits all,” experts told CURE®.

Jonathan wrightPetros grivasFred hutchFred hutchinson cancer centerBladder cancer advocacy networkUniversity of washingtonUniversity of washington center urology clinicWashington center urologyMask afterBladder cancerSelf advocateBladder cancer awareness month

Dr Grivas on Frontline Treatment Options in Metastatic RCC

Petros Grivas, MD, PhD, discusses frontline treatment options for patients with metastatic renal cell carcinoma.

Petros grivasScott tykodiUniversity of washington uw school medicineFred hutchinson cancer centerClinical research divisionDivision of hematologyGenitourinary cancers programScience summitPatients with metastatic renal cell carcinoma

Trodelvy-Keytruda Combo Shows High Promise in Metastatic Bladder Cancer

A phase 2 trial showed that Trodelvy plus Keytruda had a high response rate with lasting responses, emphasizing “potential additive or synergistic effects,” an expert said.

Petros grivasNational cancer instituteFred hutchinson cancer centerUniversity of washingtonNational cancerDifferentiating muscle invasiveNon muscle invasive bladderGetting newly approved cancer drugs mayBladder cancerGenitourinary cancersPhase 2 clinical trialsMetastatic bladder cancer